SanBio Company Limited (SNBIF)

Market Cap	409.17M -64.8%
Revenue (ttm)	n/a
Net Income	-22.82M
EPS	-0.30
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,500
Open	5.85
Previous Close	16.45
Day's Range	5.85 - 16.45
52-Week Range	5.51 - 16.45
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 15, 2026

About SanBio Company

SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company’s research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 33
• Stock Exchange: OTCMKTS
• Ticker Symbol: SNBIF

Financial Performance

Financial numbers in JPY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error